[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostate-hypertrophybph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostate-hypertrophybph":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,50,78,89,116,141,178,203,227,249,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053645","stone-and-laser-therapies-post-market-study-salt-100053645",false,"NCT06982235","Stone and Laser Therapies Post-Market Study (SALT)","Stone and Laser Therapies Post-Market Study","SALT","Inclusion Criteria:\n\nFor urinary tract procedure cohort:\n\n1. Subject intends to undergo diagnostic and\u002For therapeutic urinary tract procedure with qualified BSC device(s)\n2. Subject is willing and able to complete all follow-up visits\n\nFor BPH cohort:\n\n1. Subject is ≥ 40 years of age\n2. Subject with a diagnosis of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms\n3. Subject intends to undergo BPH treatment with qualified BSC device(s)\n4. Subject is willing and able to complete all follow-up visits\n\nExclusion Criteria:\n\nFor urinary tract procedure cohort:\n\n1. Subject requires simultaneous surgical treatment for BPH\n2. Unwilling or unable to provide consent\n3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.)\n\nFor BPH cohort:\n\n1. Subject requires simultaneous upper urinary calculi lithotripsy procedure (not applicable to bladder calculi)\n2. Unwilling or unable to provide consent\n3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.)","ALL",{"count":19,"type":20},238,"ESTIMATED","12 Months","OBSERVATIONAL","The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and\u002For therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.",[25,26,27,28,29],"Benign Prostate Hypertrophy(BPH)","Renal Calculi","Ureteral Stones, Kidney Stones","Calculi, Urinary","Urinary Tract Procedure",[31,32,33,26,34,35,36,29],"BPH","Benign Prostatic Hyperplasia","Lithotripsy","Renal Calculus","Boston Scientific","Kidney Stone","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2025-06-30",{"date":45,"type":20},"2029-02",{"name":47,"class":48},"Boston Scientific Corporation","INDUSTRY",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100644203","efficacy-and-tolerability-of-treatment-with-alfalitic-plus-serenoa-repens-compared-to-alfalitic-plus-antimuscarinic-for-moderate-severe-lower-urinary-tract-symptoms-100644203","NCT07665749","Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms","Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Mixed Lower Urinary Tract Symptoms: Results of a Cross-sectional Clinical Study","FINAL","Inclusion Criteria:\n\n* Age 40-80 inclusive\n* Male\n* With moderate-to-severe LUTS from BPH according to IPSS score\n* Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months\n\nExclusion Criteria:\n\n* Prostate or bladder cancer\n* History of neurogenic bladder\n* Urinary tract abnormalities (including urethral strictures)","MALE","40 Years","80 Years",{"count":62,"type":20},50,"The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).",[25],[31,66],"LUTS","NOT_YET_RECRUITING","2026-06-24",{"date":70,"type":41},"2026-06-26",{"date":72,"type":20},"2026-06-01",{"date":74,"type":20},"2026-11-01",{"name":76,"class":77},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",{"id":79,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":81,"keywords":82,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":88,"locationsCount":49},"100591577",{"count":19,"type":20},[25,26,27,28,29],[31,32,33,26,34,35,36,29],"2026-06-11",{"date":85,"type":41},"2026-06-12",{"date":43,"type":41},{"date":45,"type":20},{"name":47,"class":48},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":58,"minAge":96,"maxAge":60,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100643352","oxiblumecoq10-ralivia-therapy-for-benign-prostatic-hyperplasia-100643352","NCT07638865","Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:","Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.","Inclusion Criteria:\n\n1. Participant must be between 50 and 80 years old.\n2. Participant has signed and dated the appropriate Informed Consent document.\n3. International Prostate Symptom Score (IPSS) ≥8 and ≤30\n4. Prostate volume ≥30gram and ≤80gram\n5. Peak urinary flow rate (Qmax) ≥5 ml\u002Fsec and ≤15ml\u002Fsec\n6. Post void residual volume ≤150ml\n\nExclusion Criteria:\n\n1. Current or recurrent urinary tract infection (UTI), prostatitis, gross hematuria (blood in urine without a known cause), or a history of urinary retention.\n2. Participant has a history of prostate, bladder or urethral cancer.\n3. Participant has undergone pelvic radiation or systemic chemotherapy.\n4. Participant has undergone intravesical chemotherapy.\n5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition (except from BPH) associated with LUTS, any neurological disease or disorder affecting the bladder.\n6. Participant has undergone prostate surgery\n7. Participant with penile or urinary sphincter implants.\n8. Diagnosed neurological conditions known to affect bladder function (e.g., multiple sclerosis, Parkinson's disease, or neurogenic bladder).\n9. Significant medical conditions (e.g., unstable cardiac arrhythmias, uncontrolled diabetes, severe renal impairment) that pose an unreasonable risk to the patient or might interfere with study results.\n10. Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis.\n11. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.","50 Years",{"count":98,"type":20},100,"INTERVENTIONAL",[101],"NA","Objectives of the study\n\nThe aim of the study is to investigate and compare the treatment efficacy and safety of Oxiblume:CoQ10 (Ralivia) therapy vs placebo for BPH patients\n\nStudy center\n\nThe study will be coordinated by the research office of 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece. The research office will also support the project (logistics, quality control, management, data acquisition, publications).\n\nPatients visits will be carried out in the BPH Research Unit of the 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece.\n\nLaboratory tests of all patients will be performed at the same microbiology laboratory.\n\nStudy population A total of 100 patients (50 in Group A and 50 in Group B) with BPH diagnosis will participate in this study.\n\nStudy design Double-blind placebo-controlled randomized clinical trial\n\nZero hypothesis (H0) and alternative hypothesis (H1):\n\n(H0): Group A demonstrates similar efficacy compared to Group B for the treatment of BPH patients.\n\n(H1): Group A demonstrates greater or decreased efficacy compared to Group B for the treatment of BPH patients.\n\nStudy endpoints Primary endpoint: The difference between the Group A and Group B in the change of IPSS score from baseline to 12 weeks after treatment initiation.\n\nSecondary endpoints:\n\n* Adverse events rate in all patients during study period.\n* The difference between the Group A and Group B in the change of the IPSS score from baseline to 6 weeks after treatment initiation.\n* The difference between the Group A and Group B in the change of the following parameters from baseline to 6 and 12 weeks after treatment initiation\n\n  1. Qmax value\n  2. Prostate volume\n  3. Post void residual\n  4. IIEF-ED score\n  5. Psa value\n  6. TNFa, IL 6 values\n\nTreatment Visits :\n\nPatients accordingly to which group they will be randomized will receive:\n\n* Active treatment (Ralivia) Group : 1 pill of Ralivia per os\u002Fday for a 3-month period\n* Placebo Group : 1 placebo pill per os\u002Fday for a 3-month period\n\nAdverse events will be reported.\n\nFU Visit 1: 6 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.\n\nPSA TNFa, IL 1β, IL 6, IL 10 will be measured through blood test.\n\nFU Visit 2: 12 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.\n\nDRE will be performed . PSA TNFa, IL 6 will be measured through blood test.",[104,25,105],"Benign Prostate Enlargement","Benign Prostate Obstruction (BPO)","2026-06-04",{"date":108,"type":41},"2026-06-10",{"date":110,"type":20},"2026-06-08",{"date":112,"type":20},"2026-12",{"name":114,"class":77},"G.Gennimatas General Hospital",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":58,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":99,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":115},"100624061","phase-1-a-clinical-trial-to-compare-and-evaluate-evaluate-the-pharmacokinetics-and-safety-of-ckd-846-100624061","NCT07404735","A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846","A Randomized, Open-label and Parallel Study to Evaluate the Pharmacokinetics and Safety of CKD-846 in Healthy Male Subjects","Inclusion Criteria:\n\n1. Healthy man aged between 19 to 55 at screening\n2. Weight ≥ 55kg\n3. Body mass index (BMI) of 18.5 to 27.0kg\u002Fm2\n4. Those who agree to contraception from the first Investigational Product(IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial\n5. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial\n\nExclusion Criteria:\n\n1. Those who have clinically significant disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder\n2. Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and transient ischemic attack within 2 years prior to the first administration of the investigational drug\n3. Those with eye diseases including genetic degenerative retinal diseases, including retinitis pigmentosa\n4. Those with a past history of erection lasting more than 4 hours and priapism while taking PDE5 inhibitors such as tadalafil\n5. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption\n6. Persons with a history of clinically significant hypersensitivity to drugs or additives, including ingredients of clinical investigational drugs\n7. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n8. A person who is judged to be unsuitable as a test subject in a screening test conducted within 28 days before administration of the investigational drug\n9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test.\n10. Those who has taken over-the-counter or prescription drugs, excluding topical agents without significant systemic absorption, within a specified period of time and the administered drug is judged to have an effect on this test or may affect the safety of the subject\n11. People who need to take nitrate preparations or nitric oxide donors etc. regularly or intermittently during the clinical trial period\n12. Those who continuously smoke excessively or consume caffeine or alcohol\n13. A person who consumed food containing grapefruit within 7 days before the first administration of the investigational drug\n14. Persons who participated in another clinical trial (including bioequivalence test) and received an investigational drug within 180days prior to the date of first administration of the investigational drug\n15. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days\n16. Those who have received blood transfusion in 30 days\n17. Those who are deemed insufficient to participate in clinical study by investigators",true,"19 Years","55 Years",{"count":127,"type":20},32,[129],"PHASE1","A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846",[25],"2026-02-08",{"date":134,"type":41},"2026-02-11",{"date":136,"type":20},"2026-02-23",{"date":138,"type":20},"2026-06-02",{"name":140,"class":48},"Chong Kun Dang Pharmaceutical",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":58,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":99,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":5},"100614737","early-versus-delayed-trial-without-catheter-in-men-with-acute-urinary-retention-100614737","NCT07283484","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention.","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention: a Randomized Controlled Trial (the RELIEF Study).","RELIEF","Inclusion Criteria:\n\n* Adult men (≥18 years)\n* Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin)\n* Mentally competent and able to understand the potential benefits and burdens of study participation\n* Provision of written or digital informed consent\n\nExclusion Criteria:\n\n* Failed prior TWOC within the preceding 30 days\n* Initial urinary retention volume \\>1500 mL\n* Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida)\n* History of prostate cancer with ISUP grade group ≥2\n* History of active bladder cancer or ongoing surveillance for bladder cancer\n* Urinary retention occurring within 72 hours after surgery (postoperative urinary retention)\n* History of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, or prostate surgery)\n* AUR suspected to be caused by bladder stones\n* Suspected urethral stricture, clot retention, or urosepsis\n* Contraindication to alpha-blocker therapy","18 Years",{"count":151,"type":20},478,[101],"Acute urinary retention (AUR) is a sudden and painful condition. It occurs when a person is unable to urinate. In men, AUR is most often caused by an enlarged prostate, known as benign prostatic hyperplasia (BPH), which blocks the urethra. The first steps in treatment are to insert a catheter to empty the bladder and to start medication that acts on the prostate (an alpha-blocker). After some time, the catheter is removed during a so-called \"Trial Without Catheter\" (TWOC) to see whether the patient can urinate normally again.\n\nAt present, it is unclear how long a catheter should remain in place before this trial is performed. In Dutch hospitals, the duration varies widely: in some hospitals, the catheter is removed after only a few days, while in others it stays in place for two weeks or longer. A longer catheter duration can cause more discomfort and complications, such as urinary tract infections or blood in the urine. Therefore, it is important to determine whether a shorter catheterization period is equally effective and safe compared to a longer one.\n\nThe RELIEF study investigates whether a short catheter duration of three days is as safe and effective as the current average of fourteen days. A total of 478 men with acute urinary retention will participate in this nationwide randomized controlled trial. All participants will receive a catheter and start (or continue) treatment with an alpha-blocker. They will then be randomly assigned to one of two groups: one group will have the catheter removed after three days, and the other group after fourteen days.\n\nThe main question is whether a shorter catheter duration is as successful as a longer one. Success means that the patient can urinate normally after catheter removal, without needing to have the catheter replaced. The study will also compare the number of complications, patients' experiences with the catheter, their quality of life, and the overall healthcare costs.\n\nBy conducting this study, doctors will gain better evidence on the optimal timing of catheter removal in men with AUR. The goal is to avoid unnecessarily long catheterization, reduce discomfort and complications, and improve the quality of care for men with AUR. The results of the RELIEF study may help improve the management of AUR, making care more consistent, efficient, and patient-friendly both in the Netherlands and abroad.",[155,156,157,25],"Acute Urinary Retention","Benign Prostate Obstruction","Benign Prostate Hyperplasia",[147,155,159,160,161,162,163,164,165,166,167,168,31],"Urinary Retention","TWOC","Trial Without Catheter","bladder catheter","urinary catheter","catheter removal","catheter withdrawal","Benign prostate obstruction","BPO","Benign prostate hyperplasia","2025-12-15",{"date":171,"type":41},"2025-12-22",{"date":173,"type":41},"2025-08-21",{"date":175,"type":20},"2029-03-01",{"name":177,"class":77},"Liselot Ribbert",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":58,"minAge":149,"maxAge":4,"enrollmentInfo":185,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100612586","efficacy-of-prostatic-arteries-embolization-using-squidperi-100612586","NCT07255508","Efficacy of Prostatic Arteries Embolization Using SQUIDPERI","SQUID-PAE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patient scheduled for a PAE using SquidPERI as part of routine care\n* Patient informed who signed the informed consent form\n* French social security affiliation\n* Good understanding of the French language\n\nExclusion Criteria:\n\n* Patient unwilling or unlikely to comply with FU schedule\n* Known severe allergy to iodine\n* Known severe hepatic impairment\n* Vulnerable patient populations (such as patient under guardianship, curatorship, deprived of liberty)\n* Patient that already had a PAE\n* Patient on AME (state medical aid)\n* Participation in any interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable",{"count":98,"type":20},"Prostatic Artery Embolization (PAE) is a recognized mini-invasive treatment of bothersome Lower Urinary Tract Symptoms (LUTS) related to Benign Prostatic Hyperplasia (BPH). Particle embolics are used almost exclusively for embolization, with wide variation in the type and size of particles showing similar performance and safety results. Even if its durability relies on multiple risk factors, LUTS recurrence-free survival probability decreases with years. It is demonstrated that recanalization of the native prostatic artery is found in 66% of patients experiencing LUTS recurrence. Artery recanalization after several months has been reported in embolization with microparticles. The investigators addressed this issue using the liquid embolic agent SQUIDPERI in a prospective cohort of patients undergoing rePAE and showed a good clinical success rate (76.7%) at 3 months. Since then, the investigators perform initial PAE using SQUIDPERI with good results.\n\nThe aim of SQUID-PAE study is to assess the efficacy of PAE using SQUIDPERI in an initial PAE setting in a multicenter prospective study.",[25],[189,190,191,192],"Prostatic Artery Embolization","PAE","SQUIDPERI","Liquid Embolic Agent","2025-11-20",{"date":195,"type":41},"2025-12-01",{"date":197,"type":20},"2025-11",{"date":199,"type":20},"2027-11",{"name":201,"class":77},"Assistance Publique - Hôpitaux de Paris",4,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":123,"sex":58,"minAge":149,"maxAge":60,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100611313","application-of-quantum-detection-driven-artificial-intelligence-algorithms-for-single-molecule-cfdna-characterization-in-the-early-diagnosis-of-prostate-cancer-100611313","NCT07238959","Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer","Inclusion Criteria:\n\n1. Male, aged 18-80 years;\n2. PSA \\> 4 ng\u002Fml;\n3. Patients meeting criteria for prostate biopsy:\n\n   * fPSA\u002FPSA \\\u003C 0.16 or PSA D \\> 0.15 or PSA V \\> 0.75; ② Positive digital rectal examination (DRE); ③ Imaging studies (ultrasound\u002FMRI) showing suspicious lesions.\n\nExclusion Criteria:\n\n1. Patients diagnosed with any malignant tumour within the past five years;\n2. Patients who have undergone transurethral resection or enucleation of the prostate;\n3. Patients who have previously received treatment for prostate cancer, including but not limited to endocrine therapy, targeted therapy, or immunotherapy;\n4. Patients on long-term anticoagulant or antiplatelet therapy (anticoagulants discontinued for less than one week);\n5. Patients who have received any form of tumour treatment prior to enrolment blood sampling, including surgery, radiotherapy\u002Fchemotherapy, endocrine therapy, targeted therapy, or immunotherapy;\n6. Concurrent severe systemic diseases deemed by the investigator likely to interfere with trial treatment, evaluation, or compliance, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immunological, or urological disorders;\n7. Organ transplant recipients or individuals with prior non-autologous (allogeneic) bone marrow or stem cell transplantation;\n8. Subjects who have undergone blood transfusion within one month prior to blood sampling;\n9. Patients currently participating in other clinical trials, or who have participated in other clinical trials within the past year;\n10. Patients deemed unsuitable for this clinical trial by the investigator;\n11. Patients meeting any of the above criteria shall not be eligible for inclusion as subjects.",{"count":210,"type":20},1100,"This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. The ultimate objective is to establish the diagnostic efficacy of this approach through clinical validation, providing clinicians with a novel diagnostic tool capable of significantly reducing unnecessary prostate biopsy procedures.",[25,213,214],"Prostate Cancer (Diagnosis)","Prostate Neoplasm",[216,217],"Early diagnosis","cfDNA","2025-11-15",{"date":193,"type":41},{"date":221,"type":20},"2025-12",{"date":223,"type":20},"2027-12",{"name":225,"class":77},"Shanghai Changzheng Hospital",7,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":123,"sex":58,"minAge":149,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":99,"phases":236,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":115},"100594285","phase-3-trial-to-assess-the-efficacy-and-safety-during-convective-radiofrequency-water-vapor-thermal-therapy-rezum-for-benign-prostate-hyperplasia-100594285","NCT07017452","Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia","Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia","Inclusion Criteria:\n\n* Able to provide an informed consent.\n* Age ≥ 18 years\n* Biological males identified with male sexual organs.\n* Scheduled for convective radiofrequency water vapor thermal therapy (REZUM) for the management of benign prostate hyperplasia.\n\nExclusion Criteria:\n\n* Concomitant use of nephrotoxic and\u002For hepatoxic agents.\n* Use of ≥ 6 ml Penthrox withing the previous 3 weeks.\n* Known allergies and\u002For adverse events due to penthrox, other halogenated anesthetics, percocet (oxycodone + acetaminophen), lorazepam, lidocaine, midazolam, ketamine, remifentanil and propofol\n* History of genetic susceptibility to malignant hyperthermia.\n* Presence of clinically significant respiratory depression, cardiovascular instability, renal or hepatic impairment\n* Altered level of consciousness due to any cause.",{"count":235,"type":20},48,[237],"PHASE3","The primary aim of the study is to show that methoxyflurane-lorazepam-percocet combination administrated 'per os' is non inferior to deep intravenous sedation in achieving analgesia during Rezum convective radiofrequency water vapor thermal therapy for the management of benign prostate hyperplasia (BPH). We propose to conduct a single-centered, unblinded, randomized controlled trial designed after consulting ICH Guidelines for Good Clinical Practice as well the regulations set by the Biomedical Research Ethics Board, University of Manitoba.",[25],"2025-06-11",{"date":242,"type":41},"2025-06-12",{"date":244,"type":20},"2025-08",{"date":246,"type":20},"2026-06",{"name":248,"class":77},"University of Manitoba",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":123,"sex":58,"minAge":96,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":99,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":263,"locationsCount":115},"100594284","phase-3-investigating-the-adjunctive-use-of-mirabegron-in-the-early-post-rezum-procedure-period-100594284","NCT07017439","Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period","Investigating the Adjunctive Use of B3-agonist in the Early Post-Rezum Procedure Period: A Randomized Controlled Trial","Inclusion Criteria:\n\n* age \\>50, symptomatic LUTS with IPSS ≥ 10\n* prostate volume 30-80cc on any imaging modality\n* Qmax between 5 and 15ml\u002Fs with minimum voided volume of 125cc\n* frequency ≥ 8 voids\u002Fday.\n\nExclusion Criteria:\n\n* PVR greater than 300ml\n* active UTI within past week\n* previous surgical intervention for BPH\n* documented urethral stricture disease\n* bladder stones\n* active malignancy\n* any confirmed or suspected neurologic disease\n* hypertension\n* known insensitivity to B3 agonist\n* current catheter dependence\n* currently taking anticholinergic or B3 agonist.",{"count":62,"type":20},[237],"The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.",[25],{"date":242,"type":41},{"date":244,"type":20},{"date":246,"type":20},{"name":248,"class":77},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":58,"minAge":149,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":99,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":115},"100580628","safety-and-efficacy-of-milep-versus-standard-eep-100580628","NCT06839768","Safety and Efficacy of MILEP Versus Standard EEP","The MILES Trial: Prospective Randomized Trial of Safety and Efficacy of Minimally-invasive Versus Standard Laser Enucleation of the Prostate","MILES","Inclusion Criteria:\n\nLUTS presence, proven by:\n\n1. IPSS questionnaire (Score \\>20);\n2. OR uroflowmetry result (Qmax \\\u003C10 ml\u002Fs);\n\nExclusion Criteria:\n\n* Prostate volume \\> 120 cc\n* Prostate cancer on pathology;\n* Urethral strictures;\n* Bladder calculi;\n* Prior prostate surgery;\n* Neurogenic bladder dysfunction.","85 Years",{"count":274,"type":20},340,[101],"Endoscopic enucleation of the prostate (EEP) is a standard treatment for benign prostatic hyperplasia (BPH), with modifications such as MiLEP that utilizes smaller instruments. The reduced resectoscope diameter in MiLEP may help decrease rates of stress urinary incontinence (SUI) and urethral strictures.\n\nObjective: to compare the efficacy and safety of MiLEP and standard EEP with a thulium fiber laser (TFL).",[25,278],"LUTS(Lower Urinary Tract Symptoms)","2025-02-17",{"date":281,"type":41},"2025-02-21",{"date":283,"type":41},"2024-03-14",{"date":285,"type":20},"2025-05",{"name":287,"class":77},"Sechenov University"]